Otium Capital, the family office of French entrepreneur Pierre-Edouard Stérin, founder of the SmartBox Group, is investing in Quantum Genomics’ new funding round in the amount of of €20M. The deal will help the company to advance its ongoing clinical research and strengthen its industrial production and commercial operations.
Quantum Genomics: biotech startup focused on cardiovascular drugs
The company, which is listed in the Euronext Growth Exchange in Paris, is specialized in the development of a new class of cardiovascular drugs acting directly on the brain to treat difficult-to-treat/resistant arterial hypertension and heart failure.
Quantum Genomics‘ goal is to develop innovative treatments for complicated, or even resistant, cases of hypertension (around 30% of patients have poor control of their condition or receive ineffective treatment) and for heart failure (one in two patients diagnosed with severe heart failure dies within five years).
Otium Capital: leading French single family office in venture capital
Pierre-Edouard Sterin, SmartBox’s founder and CEO, owns a very strong but diversified portfolio of investments in companies from the consumer goods, entertainment, tech, B2B, and healthcare industries through his family office Otium Capital. Also, some of Otium’s portfolio companies already successfully exited, standing out the one from La Fourchette, “one of the most successful startup exits in France by that time”.
Relevant family office articles
- Overview of the largest Multi Family Offices from Paris
- Hermès – Dumas Family: Is there a single family office?
- Dell and Rubenstein Family Office Invest $85M In Lindblad Expeditions